| Literature DB >> 30616472 |
Yanling Ren1,2, Huifang Jiang3, Fangjing Shi4, Li Ye1,2, Yingwan Luo1,2, Xinping Zhou1,2, Chen Mei1,2, Liya Ma1,2, Weilai Xu1, Peipei Lin1,2, Chao Hu1,2, Jie Jin1,3, Hongyan Tong1,2.
Abstract
We retrospectively studied 133 myelodysplastic syndrome patients receiving decitabine during January 2009 and September 2017. The dose of 15 mg/m2/d (n = 83) and 20 mg/m2/d (n = 50) had comparable overall response rates (ORR) (51.8% vs. 52.00%) and complete remission rate (CRR) (15.66% vs. 22.00%). The 15 mg/m2/d group had a lower incidence of grade 3/4 neutropenia (60.24% vs. 88.00%, p < .05) and thrombocytopenia (65.06% vs. 88.00%, p < .05). The 15 mg/m2/d group had a longer median overall survival (OS) (21.60 months vs. 15.23 months, p = .02). The same results were seen in refractory anemia with excess blasts (RAEB) patients: The 15 mg/m2/d group also had comparable ORR, CRR, decreased hematological toxicities and longer OS. Further analysis suggested that survival benefit of 15 mg/m2/d group was mainly in those patients with lower risk stratification. In conclusion, 15 mg/m2/d decitabine is associated with a lower incidence of hematological toxicities and longer OS and may be more suitable for patients with relatively lower risk.Entities:
Keywords: Myelodysplastic syndrome; decitabine; dosage; refractory anemia with excess blasts
Year: 2019 PMID： 30616472 DOI： 10.1080/10428194.2018.1546853
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022